The CDA-AMC has proposed to make changes to numerous aspects of the reimbursement review program. Jointly with Innovative Medicines Canada, BIOTECanada proposed to keep the current model for draft and final recommendations and refocusing the CDA-AMC reform effort on potential changes that would more directly address the current global pharmaceutical policy dynamics.
For more information, please contact Pascale Lajoie: pascale.lajoie@biotech.ca